Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03980223 · ClinicalTrials.gov registry record · Phase 4
Evaluation of Doxycycline Post-exposure Prophylaxis to Reduce Sexually Transmitted Infections in PrEP Users and HIV-infected Men Who Have Sex With Men
A Phase 4 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 641
- Enrollment target
NCT03980223 is a Phase 4 study that has completed, run by University of California, San Francisco. The registered enrollment target is 641 participants.
The verdict
NCT03980223, a Phase 4 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 641 participants
- Enrollment target
Study Summary
The purpose of this study is to understand if taking an antibiotic called doxycycline by mouth as soon as possible after sexual contact without a condom can reduce the risk of sexually transmitted infections (STIs), including gonorrhea, chlamydia and syphilis. The study will also look at the safety of doxycycline PEP and the impact that PEP may have on the bacteria that cause STIs as well as on bacteria that normally live on the body. While doxycycline is approved by the Food and Drug Administration (FDA), taking doxycycline immediately after sexual contact to prevent infection is investigational and is not approved by the FDA for this use. Participants will take part in the study for 1 year.
Interventions
- DRUG Doxycycline Hyclate Delayed-Release 200 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 641 participants |
| Start Date | 2019-11-26 |
| Est. Completion | 2023-06-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03980223
The ClinicalTrials.gov registry entry for NCT03980223 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 641 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Doxycycline Hyclate Delayed-Release 200 mg is the first listed.
NCT03980223 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03980223 about?
NCT03980223 is a clinical study titled "Evaluation of Doxycycline Post-exposure Prophylaxis to Reduce Sexually Transmitted Infections in PrEP Users and HIV-infected Men Who Have Sex With Men". The purpose of this study is to understand if taking an antibiotic called doxycycline by mouth as soon as possible after sexual contact without a condom can reduce the risk of sexually transmitted infections (STIs), including gonorrhea, chlamydia and syphilis. The study will also look at the safety ...
What is the current status of trial NCT03980223?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 641 participants. The study started on 2019-11-26. Estimated completion is 2023-06-12.
What interventions are being tested in trial NCT03980223?
The interventions under investigation include: Doxycycline Hyclate Delayed-Release 200 mg (DRUG).
Who is sponsoring clinical trial NCT03980223?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.